Rangering i aksjer
#20648
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Aksjekurs
$0.517
Sist synkronisert: 2026-08-21
Handel Vaxart, Inc. (VXRT)
Pris VXRT pris med markedsverdi på B
Markedsverdi av Vaxart, Inc.(VXRT)
Markedsverdi: $125.14M
Per August 2026 har Vaxart, Inc. en markedsverdi på $125.14M. Dette gjør Vaxart, Inc. til det 20648th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Vaxart, Inc. fra 1981 til 2026
VXRT sammenlignet med topp 5 mest populære stocks
| Pris på VXRT |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.211T
|
+4,164,442.00%
|
|
|
|
|
$4.547T
|
+3,633,324.35%
|
|
|
|
|
$4.162T
|
+3,326,244.06%
|
|
|
|
|
$3.593T
|
+2,870,993.60%
|
|
|
|
|
$2.793T
|
+2,231,743.37%
|
